Praxis Precision Medicines (PRAX) Income towards Parent Company (2019 - 2026)

Praxis Precision Medicines' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$562.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 641.16% year-over-year to -$562.1 million in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 142.84% decrease from a year earlier, with the FY2025 full-year figure at -$736.1 million, down 75.91% from the prior year.
• Income towards Parent Company slipped to -$562.1 million in Q1 2026 per PRAX's latest filing, from -$403.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$25.7 million in Q3 2023 and bottomed at -$562.1 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$75.8 million (2025), against an average of -$137.2 million.
• Across the five-year window, Income towards Parent Company surged 54.43% in 2023 and plunged 641.16% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$184.1 million in 2022, then retreated by 13.17% to -$208.3 million in 2023, then sank by 35.5% to -$282.3 million in 2024, then slumped by 43.01% to -$403.6 million in 2025, then slumped by 39.25% to -$562.1 million in 2026.
• Per Business Quant, the three latest PRAX Income towards Parent Company figures stand at -$562.1 million (Q1 2026), -$403.6 million (Q4 2025), and -$87.0 million (Q3 2025).